Riskpilot← Back to searchSign inGet full accessImmunovia AB (publ)
ABActiveOrg 5567304299StockholmOther human health activities n.e.c. · NACE 8699Est. 20071-4 employees
Revenue 2024
SEK 931K
-93% vs 2023
EBITDA margin
-6242.0%
+27% vs 2023
Equity ratio
31.6%
Financial strength
Net profit 2024
SEK -107M
+63% vs 2023
| Revenue | SEK 931K | -93% |
| EBITDA | SEK -58,1M | +27% |
| Net profit | SEK -107M | +63% |
| Total assets | SEK 26,4M | -67% |
| Equity | SEK 8,4M | -87% |
| Employees | — | — |
Legal name
Immunovia AB (publ)
Org number
5567304299
Legal form
Aktiebolag
NACE code
8699 · Other human health activities n.e.c.
Founded
24 maj 2007
Share capital
SEK 5 091 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas av Höngård Andersen, Peter i förening med Borcherding, Jeffrey Paul Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Aktiebolagets verksamhet ska vara att ägna sig åt diagnostik av sjukdomar samt därmed förenlig verksamhet.
Address
Stockholm
Phone
+46462756000
Email
finance@immunovia.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 362 | 9 987 | 24 725 | 12 977 | 931 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −97 607 | −110 837 | −89 203 | −79 762 | −58 113 |
| Depreciation & amort. | −3 310 | −11 685 | −16 928 | −134 186 | −1 204 |
| EBIT | −100 917 | −122 522 | −106 131 | −213 948 | −59 317 |
| Net financials | −23 952 | 13 159 | −242 256 | −93 871 | −47 661 |
| Profit before tax | −108 814 | −106 572 | −331 147 | −292 750 | −106 978 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −108 814 | −106 572 | −331 147 | −292 750 | −106 978 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 699 486 | 591 306 | 252 345 | 80 587 | 26 428 |
| Equity | 672 158 | 565 586 | 234 439 | 62 933 | 8 364 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 27 328 | 25 720 | 17 906 | 17 654 | 12 356 |
| Total debt | 27 328 | 25 720 | 17 906 | 17 654 | 12 356 |
EBITDA margin
-6242.0%
This company
15.8%
Market median
-39606% vs market
20202024
Equity ratio
31.6%
This company
38.2%
Market median
+17% vs market
20202024
Return on equity
-1279.0%
This company
18.4%
Market median
-7051% vs market
20202024
Net profit margin
-11490.7%
This company
8.1%
Market median
-141960% vs market
20202024
Asset turnover
0.04×
This company
1.12×
Market median
-96% vs market
20202024
Debt / equity
2.16×
This company
0.62×
Market median
-248% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
UM | Audit | 2025 |
JP Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (5) | ||
ML | Audit | 2020 – 2025 |
MP Chief Executive Officer | Chief Executive Officer | 2020 – 2020 |
KM External Signatory | External Signatory | 2020 – 2025 |
PO Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
UK Chief Executive Officer | Chief Executive Officer | 2020 – 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
| Board of Directors | 2020 | |
| Board of Directors | 2020 | |
| Board of Directors | 2025 | |
| Chairman | 2020 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Former (6) | ||
| Board of Directors | 2023 – 2023 | |
| Board of Directors | 2020 – 2025 | |
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2023 – 2023 | |
| Chairman | 2023 – 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Immunovia AB (publ) (this company)
Immunovia GmbhBoard members of Immunovia AB (publ) also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mats-Åke Lennart Andersson | Audit | 0 companies |
| Mats Peter Egon Grahn | Chief Executive Officer | 0 companies |
| Karin Maria I Almqvist Liwendahl | External Signatory | 0 companies |
| Ulf Martin Ingvar Gustafsson | Audit | 0 companies |
| Patrik Olof Dahlén | Chief Executive Officer | 0 companies |
| Ulla Kerstin Mimmi Ingegerd Ekberg | Chief Executive Officer | 0 companies |
| Jeffrey Paul Borcherding | Chief Executive Officer | 0 companies |
| Philipp Sixt Lothar von Hugo | Board of Directors | 0 companies |
| Stig Michael Emerik Löfman | Board of Directors | 0 companies |
| Christofer Gustav Olof Sjögren | Board of Directors | 0 companies |
| Ann-Christin Margareta Sundell | Board of Directors | 0 companies |
| Martin Brygger Møller | Board of Directors | 0 companies |
| Eric Sten Krafft | Board of Directors | 0 companies |
| Hans Olof Gunnar Johansson | Board of Directors | 0 companies |
| Richard Bryan Riggsbee | Board of Directors | 0 companies |
| Peter Høngård Andersen | Chairman | 0 companies |
| Karl Arne Krister Borrebaeck | Chairman | 0 companies |
| Melissa Ann Farina | Board of Directors | 0 companies |
| Valerie Anne Bogdan-Powers | Board of Directors | 0 companies |